#None #WuXi Biologics #HanchorBio #fusion proteins

Strategic Partnership between HanchorBio and WuXi Biologics

In a significant move for the biotech industry, HanchorBio, a clinical-stage company specializing in immunotherapy, has entered into a strategic partnership with WuXi Biologics, a leading Contract Research, Development, and Manufacturing Organization (CRDMO). This collaboration is set to bolster the development and manufacturing of innovative bi- and multi-functional fusion proteins targeted towards oncology and autoimmune diseases. The alliance was formally announced on January 26, 2026.

HanchorBio, whose mission focuses on creating next-generation immunotherapies, seeks to leverage this partnership to enhance its pipeline of products derived from its Fc-Based Designer Biologics (FBDB™) platform. Under the agreement, WuXi Biologics will provide comprehensive biologics development services, encompassing everything from cell line development to GMP manufacturing. This comprehensive approach is expected to not only speed up the clinical translation of HanchorBio's therapies but also enhance the efficiency of their Chemistry, Manufacturing, and Controls (CMC) processes.

HanchorBio's Chairman, Scott Liu, emphasized the importance of this collaboration, stating, "This partnership with WuXi Biologics bolsters our capacity to translate platform-driven innovation into high-quality assets for clinical and commercial use. As we advance multiple fusion protein programs, the need for speed, reliability, and scalability in manufacturing cannot be overstated. WuXi's prowess in managing complex biologics makes them an ideal partner in our journey."

The collaboration comes at a time when the demand for advanced drug therapies is increasing. WuXi Biologics brings to the table extensive experience in handling complex biologic modalities, including bispecific antibodies, antibody-drug conjugates (ADCs), and fusion proteins. As of 2025, the company has supported nearly 945 projects, a testament to their reliability and expertise in navigating the complexities of biologic drug development.

One particularly exciting aspect of this partnership is the potential for HanchorBio to continue expanding their proprietary FBDB™ technology. This platform is dedicated to the design of multi-functional fusion proteins which are specifically engineered to modulate both innate and adaptive immunity, addressing several key challenges present in current oncology treatments. The intent is to enhance therapeutic outcomes and improve patient responses.

Dr. Chris Chen, CEO of WuXi Biologics, stated, "We are thrilled to embark on this collaboration with HanchorBio. Our combined efforts will significantly accelerate the development of innovative fusion proteins and help introduce transformative therapies to patients globally. By utilizing our industry-leading technology platforms and our commitment to quality, we aim to create impactful biologics that can redefine treatment methodologies."

This partnership marks a crucial turning point for both organizations, aligning HanchorBio's innovative discoveries with WuXi Biologics’ operational excellence and global reach. As the two companies work together over the coming months and years, the biopharmaceutical landscape may witness the emergence of new therapies that could dramatically reshape standards in cancer and autoimmune disease treatment.

HanchorBio operates in several key locations including Taipei, Shanghai, and the San Francisco Bay Area, focusing on developing immuno-oncology therapies and treatments for immune-mediated conditions using their state-of-the-art FBDB™ platform. For more information on HanchorBio and their innovative solutions, you can visit their official website.

Meanwhile, WuXi Biologics remains committed to sustainability and promoting green technology innovations within the biopharmaceutical sector. They strive to offer advanced solutions while maintaining high environmental, social, and governance (ESG) standards, creating shared value across the industry.

As these two leaders in biotechnology join forces, the future looks promising not only for them but also for patients who stand to benefit from their groundbreaking research and development efforts.